ArticleMedicine2025
Exploration of the effects of 66 mitochondria-associated proteins on different cardiomyopathies: A bidirectional 2-sample mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics.Molecular neurobiology · 2026Review
- Mitophagy in Hepatic Ischemia-Reperfusion Injury: From Mitochondrial Dysfunction to Therapeutic Targeting.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aim of this study was to apply bidirectional Mendelian randomization (MR) to assess and investigate the causal associations between mitochondrial DNA copy number (mtDNA-CN), mitochondrial-associated proteins and cardiomyopathy. The mtDNA-CN and MAP from the IEU Open GWAS database were screened for strong associations with 4 different cardiomyopathy-associated single nucleotide polymorphisms (SNPs) in the IEU Open GWAS and Finnish databases, respectively, and causal associations were investigated using the inverse variance weighting method, the MR-Egger regression method, the weighted median method, the weighted mode method, and the simple mode method. method to explore causality; meanwhile, we used the Cochran Q test to assess the variability of SNPs. Horizontal pleiotropy of SNPs was examined by MR-Egger regression analysis and MR-PRESSO method. Sensitivity analyses were performed using the "Leave-One-Out (LOO)" method to determine whether the MR results would be interfered by a single SNP. MR analyses of mtDNA-CN, mitochondria-associated proteins, and different cardiomyopathies, respectively, with IVW as the primary analytical method, showed a statistically significant association between mtDNA-CN and pharmacological cardiomyopathy, P < .05. Statistical significance was found between 2 mitochondria-associated proteins (dihydrolipoyl dehydrogenase, mitochondrial apoptosis-inducing factor 1) and hypertrophic cardiomyopathy, both with P < .05. Six mitochondria-associated proteins (mitochondrial 39S ribosomal protein L33, ribosomal recycling factor, mitochondrial leucine-rich pentatricopeptide repeat motif-containing protein, serine protease high-temperature requirement protease A2, mitochondrial peptide methionine sulfoxide reductase, and mitochondrial input endomembrane transporter enzyme subunit translocase of inner mitochondrial membrane 14) and dilated cardiomyopathy were statistically significant, both with P < .05. Screening for 2 mitochondria-associated proteins (nicotinamide adenine dinucleotide dehydrogenase [ubiquinone] flavoprotein 2, and mitochondrial input endomembrane transporter enzyme subunit translocase of inner mitochondrial membrane 14, prot-a-847) and alcoholic cardiomyopathy was statistically significant，P < .05. Statistical significance was found between 1 mitochondria-associated protein (mitochondrial peptide chain release factor 1) screened and pharmacological cardiomyopathy, P < .05. Sensitivity analyses of all MR results: the Cochran Q test, MR-Egger intercept test, MR-Presso global test, and LOO sensitivity test No significant heterogeneity or horizontal pleiotropy was found at any time (all P > .05). There were causal associations between mtDNA-CN, mitochondria-associated proteins and cardiomyopathy, and mtDNA-CN and mitochondria-associated proteins had a certain predictive value for the condition and prognosis of patients with cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.